Lupin is trading at RS. 2034.80, down by 16.50 points or 0.80% from its previous closing of RS. 2051.30 on the BSE.

The stock opened at RS. 2039.95 and has touched a high of RS. 2057.00 and a low of RS. 2016.80 so far, with 18,567 shares traded on the counter.

The BSE group 'A' stock with a face value of RS. 2 recorded a 52-week high of RS. 2403.45 on January 2, 2025, and a 52-week low of RS. 1774.00 on April 7, 2025. Over the past week, it hit a high of RS. 2063.60 and a low of RS. 1974.25. The company’s current market capitalization stands at RS. 92881.03 crore.

Promoters hold 46.90% of the shares, while institutions and non-institutions own 46.81% and 6.28% respectively.

The U.S. Food and Drug Administration (USFDA) has completed an inspection of Lupin’s Nagpur Injectable facility, conducted between September 8 and September 16, 2025. The inspection concluded with six observations.

Lupin stated it will address these observations and respond to the USFDA within the stipulated timeframe, reaffirming its commitment to comply with current Good Manufacturing Practice (CGMP) quality standards across all facilities.

Lupin is an innovation-led global pharmaceutical company engaged in the production, development, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).